NIKKEI 225
38,339.57 +265.59 (+0.70%) HANG SENG
18,689.60 +151.79 (+0.82%) CRUDE OIL
79.66 +0.40 (+0.50%) GOLD FUTURES
2,358.20 +17.90 (+0.76%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,180.99 +1,025.16 (+2.09%)
PFE Oct 2024 37.000 call
| Previous close | 0.1000 |
| Open | 0.0900 |
| Bid | 0.0900 |
| Ask | 0.1200 |
| Strike | 37.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.0900 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 340 |
BloombergModerna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th
BenzingaSecond Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Investor's Business DailyPfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?
